| Patient | Audre Lorde |
|---|---|
| Date of birth | 1934-02-18 |
| Identifiers | MRN HR-ML016-SYN-TD; SSN (made up) 000-16-2937 |
| Document date | 1979-09-28 |
| Author | Naomi Fairweather, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Survivorship visit one year after diagnosis, after the yearly mammogram. [S]
Ms. Lorde returns one year after her diagnosis. Her diagnostic mammogram of the left breast a week ago showed no suspicious findings (BI-RADS 1). She has taken tamoxifen daily for eleven months. Her hot flashes remain mild, one or two a day. Her periods are regular with no bleeding between them. She has no leg swelling, breathlessness, bone pain, cough, headaches, abdominal pain, or new lumps, and no arm swelling. She walks about 30 minutes most days. Her genetic counseling appointment is next week. [S]
| Element | Detail |
|---|---|
| Interval change | Left mammogram BI-RADS 1 a week ago |
| Tamoxifen | Eleven months, taken daily |
| Recurrence symptoms | None |
| Gynecologic | Regular periods; no intermenstrual bleeding |
| Genetic counseling | Next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; no night sweats |
| Endocrine | Positive | One or two mild hot flashes a day |
| Genitourinary | Negative | No abnormal vaginal bleeding |
| Cardiovascular | Negative | No leg swelling or chest pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 1978-10-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-09-28 | Body height | 168 | cm | S |
| 1979-09-28 | Body weight | 71.8 | kg | S |
| 1979-09-28 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 1979-09-28 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1979-09-28 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1979-09-28 | Heart rate | 72 | /min | S |
| 1979-09-28 | Respiratory rate | 14 | /min | S |
| 1979-09-28 | Body temperature | 36.6 | Cel | S |
| 1979-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-09-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 1979-09-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Breasts and chest wall | Right chest wall flat, no nodules or skin change; left breast without masses |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumference 29.0 cm on each side; calves soft and non-tender |
| Abdomen | Soft; liver not enlarged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1931 breast cancer and mastectomy | active | confirmed | C50.411 | S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesis | active | confirmed | Z90.11 | S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own. |
| Long-term use of tamoxifen as adjuvant endocrine therapy | active | confirmed | Z79.810 | S — Synthetic treatment status. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No symptoms or signs of recurrence |
| Medication safety | Tamoxifen adherence and side effects | Every visit | Completed today | Taken daily for eleven months |
| Survey | Vasomotor symptom assessment | Periodically on endocrine therapy | Completed today | One or two mild hot flashes a day |
| Examination | Abnormal vaginal bleeding inquiry on tamoxifen | Every visit | Completed today | Regular periods; no intermenstrual bleeding; yearly gynecologic assessment booked for the preventive visit |
| Examination | Venous thromboembolism symptom inquiry on tamoxifen | Every visit | Completed today | No leg swelling, calf pain, or breathlessness |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Up to date | Done a week ago: BI-RADS 1; next in one year |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | No swelling; arm circumferences equal |
| Survey | Depression screen (PHQ-2) | At periodic intervals | Completed today | PHQ-2 score 0 |
| Survey | Fatigue, cognitive concerns, and sexual or vaginal symptoms | At each visit or periodically | Completed today | None reported |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended in asymptomatic stage I to III survivors | Not indicated | No symptoms to prompt testing; none ordered |
| Imaging | CT, bone scan, PET, or other imaging for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms; not ordered |
| Imaging | Bone density (DXA) | Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopause | Not indicated | Premenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise |
| Referral | Genetic counseling | Once | Referred | Appointment next week |
| Self-management | Survivorship care plan | Within one year of completing primary treatment | Completed today | Written plan given and copied to medical oncology |
| Self-management | Healthy lifestyle counseling and second-cancer screening | Every visit | Completed today | Walking about 200 minutes a week; cervical and colorectal screening to be addressed at the preventive visit next month |
Goal progress:
Guideline basis: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol 2013;31(7):961-965 (2013); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Genetic counseling next week. Adult preventive visit next month. Survivorship visit in January. Next scheduled visit 1979-10-19: adult preventive visit. [S]